Developing SHP2-based combination therapy for KRAS-amplified cancer

Gastroesophageal adenocarcinomas (GEAs) harbor recurrent amplification of KRAS, leading to marked overexpression of WT KRAS protein. We previously demonstrated that SHP2 phosphatase, which acts to promote KRAS and downstream MAPK pathway activation, is a target in these tumors when combined with MEK...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Tianxia, Kikuchi, Osamu, Zhou, Jin, Wang, Yichen, Pokharel, Babita, Bastl, Klavdija, Gokhale, Prafulla, Knott, Aine, Zhang, Yanxi, Doench, John G., Ho, Zandra V., Catenacci, Daniel V.T., Bass, Adam J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977440/
https://www.ncbi.nlm.nih.gov/pubmed/36752207
http://dx.doi.org/10.1172/jci.insight.152714

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977440/
https://www.ncbi.nlm.nih.gov/pubmed/36752207
http://dx.doi.org/10.1172/jci.insight.152714

Ejemplares similares